Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Validation of the imatinib-therapy failure model

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Data availability

The data that support the findings of this study are available from the corresponding author upon request.


  1. Zhang XS, Gale RP, Huang XJ, Jiang Q. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors? Leukemia. 2022;36:482–91.

    Article  PubMed  Google Scholar 

  2. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017;376:917–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, et al. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood. 2012;119:5963–71.

    Article  CAS  PubMed  Google Scholar 

  6. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27:6041–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–20.

    Article  CAS  PubMed  Google Scholar 

  8. Zhang XS, Gale RP, Zhang MJ, Huang XJ, Jiang Q. A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy. Leukemia. 2022;36:1336–42.

    Article  CAS  PubMed  Google Scholar 

Download references


We would like to thank the following medical staffs who provided patients data: Xiaohui Suo, Weihua Zhang and Yuanjun Zheng, Lijie Yang, Zhiqiang Sun, Rongxia Wei, Jijun Wang and Lan Ma, Qingshu Zeng, Zhen Xiao, Junxia Meng and Xiaonan Zhang, Hebing Zhou, Congmeng Lin, Pengliang Xin, Yanping Ma and Xiaoyan Ge, Yujuan Yang, Yujing and Lijun Wang, Huanling Zhu, Ling Pan and Yunfan Yang, Xingxia Zhang, Hongguo Zhao and Hairong Fei, Yonghuai Feng, Linhua Yang, Xiaoyi Lv, Hai Yi and Yilan Liu, Yun Zeng, Hua Fan, Liling Zheng, Jianmin Luo, Jianhui Qiao, Luoming Hua, Shasha Zhao, Yin Sai, Ronghua Hu, Lianyu Shen, Li Ding, Fang Ye, Shunjie Wu, Min Ouyang and Meixiang Zhao, Qin Li, Liru Wang, Wangxiang Huang, Wenqian Li, Jianli Wang, Yun Li and Jing Liu. QJ acknowledges support from the National Natural Science Foundation of China (No. 81970140). RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme.


Funded, in part, by the National Nature Science Foundation of China (No. 81970140) and CAMS Innovation Fund for Medical Sciences (CIFMS) (No. 2019-I2M-5-034).

Author information

Authors and Affiliations



QJ designed the study. QJ, XSZ, and RPG analyzed the data. QJ, XJH, XSZ and RPG prepared the typescript. QJ, XJH, BCL, JH, YLZ, XD, JYW, WML, XLL, NX, CYC, HL, GHL, RL, ZGL, XDW, YQZ, YQH, CSL, JDH, LL, ZYZ, WY, ZFL, LM, CQT, ZPZ, YLB, HYQ, SNC, FL, JXG, ZLL, HS, LZ, RF and XLS provided the most part of patients data in this study. All authors approved the final typescript, take responsibility for the content and agree to submit for publication.

Corresponding authors

Correspondence to Xiaojun Huang or Qian Jiang.

Ethics declarations

Competing interests

RPG is a consultant to NexImmune Inc. and Ananexa Pharma Ascentage Pharm Group, Antengene Biotech LLC, Medical Director, FFF Enterprises Inc.; partner, AZAC Inc.; Board of Directors, Russian Foundation for Cancer Research Support; and Scientific Advisory Board: StemRad Ltd.

Ethics approval

Approved by the Ethics Committee of People’s Hospital Beijing compliant with principles of the Helsinki Declaration.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhang, X., Gale, R.P., Liu, B. et al. Validation of the imatinib-therapy failure model. Leukemia 37, 1166–1169 (2023).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


Quick links